aTyr Pharma, Inc. (ATYR)

aTyr Pharma's stock price experienced significant volatility in the past six months. On September 15, 2025, the company announced that its Phase 3 EFZO-FIT™ study for efzofitimod failed to meet its primary endpoint, causing the stock price to plummet over 80%. This event triggered multiple securities class action lawsuits against aTyr Pharma, Inc. Prior to this, between October 23, 2024, and October 22, 2025, the share price experienced a decline of 70.54%.

aTyr Pharma, Inc. does not exhibit traditional demand seasonality for its products or services, as it is a clinical-stage biotechnology company focused on drug development rather than commercial product sales. The company's revenue trends have been flat, with its focus on advancing drug candidates through clinical trials.

aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative medicines using its tRNA synthetase biology platform, primarily targeting fibrosis and inflammation. Their lead therapeutic candidate, efzofitimod (ATYR1923), is in clinical development for inflammatory lung diseases like pulmonary sarcoidosis and interstitial lung disease.

aTyr Pharma, Inc. is headquartered in San Diego, California, with operations extending to Hong Kong and the US. The company's clinical development programs involve international collaborations and trial sites, indicating a global approach to research and patient reach.

aTyr Pharma's brand reputation has been significantly impacted by the failure of efzofitimod in the Phase 3 EFZO-FIT™ study in September 2025. This clinical setback and the subsequent stock price drop have led to investor scrutiny and securities class action lawsuits, negatively affecting the company's reputation.

aTyr Pharma, Inc. has a mixed ownership structure including institutional shareholders, individual investors, and insiders. Institutional investors hold a significant portion of the company's stock. Major institutional owners include Federated Hermes, Inc., Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Insiders own a smaller percentage, while retail investors hold a variable percentage. Sofinnova Venture Partners IX LP is a large individual shareholder.